Sassicaia Capital Advisers LLC Makes New Investment in Aethlon Medical, Inc. (NASDAQ:AEMD)

Sassicaia Capital Advisers LLC acquired a new stake in Aethlon Medical, Inc. (NASDAQ:AEMD) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 36,000 shares of the medical equipment provider’s stock, valued at approximately $31,000. Aethlon Medical makes up approximately 0.7% of Sassicaia Capital Advisers LLC’s holdings, making the stock its 6th biggest position. Sassicaia Capital Advisers LLC owned 0.26% of Aethlon Medical as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Virtu Financial LLC acquired a new position in Aethlon Medical during the fourth quarter worth $81,000. Allegiance Financial Group Advisory Services LLC bought a new stake in shares of Aethlon Medical in the 4th quarter worth about $26,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Aethlon Medical during the 4th quarter worth about $25,000. 1.99% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on AEMD shares. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Aethlon Medical in a research report on Monday, March 10th. StockNews.com began coverage on Aethlon Medical in a research report on Monday, April 21st. They set a “sell” rating on the stock.

Aethlon Medical Stock Up 1.6 %

Aethlon Medical stock opened at $0.38 on Friday. The stock has a 50-day simple moving average of $0.42 and a 200 day simple moving average of $0.49. The stock has a market capitalization of $6.12 million, a price-to-earnings ratio of -0.24 and a beta of 1.71. Aethlon Medical, Inc. has a 12-month low of $0.24 and a 12-month high of $1.79.

Aethlon Medical (NASDAQ:AEMD) last announced its earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.09. As a group, sell-side analysts anticipate that Aethlon Medical, Inc. will post -0.73 EPS for the current year.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.